Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.

Current cancer drug targets - 1 Jan 2020

Becker Justin S, Fathi Amir T

Abstract excerpt

The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has illuminated subclasses of the disease, with distinct driver mutations, that might be responsive to targeted therapies. Approximately 15-23% of AML genomes harbor mutations in one of two isoforms of isocitrate dehydrogenase (IDH1 or IDH2). These enzymes are constitutive mediators of basic cellular metabolism, but their mutated forms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Differentiation
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to Isocitrate Dehydrogenase

Share to Isoenzymes

Share to Leukemia, Myeloid, Acute

Share to Treatment Outcome

Source

Identifiers

PMID: 32329690
DOI: 10.2174/1568009620666200424145622

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.PMID 32329690Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.Semantic proximity Read ↗

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.Semantic proximity Read ↗

The role of IDH mutations in acute myeloid leukemia.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending QuestionsSemantic proximity Read ↗

IDH Inhibitors in AML-Promise and Pitfalls.Semantic proximity Read ↗

Targeting the IDH2 Pathway in Acute Myeloid Leukemia.Semantic proximity Read ↗

Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.Semantic proximity Read ↗

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches.Semantic proximity Read ↗

Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.Semantic proximity Read ↗

IDH mutations in cancer and progress toward development of targeted therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.